1-20 of 23
Ian M. Bouligny
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Shifting Treatment Paradigms and Clinical Outcomes in TP53 Mutated Acute Myeloid Leukemia

Hyun Lee, Luke Kicklighter, Thuy Ho, George Avetian, Graeme F Murray, Natasha Dziarnowski, Ian M. Bouligny, Keri Maher
Journal: Blood
Blood (2024) 144 (Supplement 1): 7909.
https://doi.org/10.1182/blood-2024-206123
Published: 2024
Journal Articles

Older Age at Time of Allogeneic Stem Cell Transplant Is Associated with Inferior Outcomes in Patients with Acute Myeloid Leukemia

George Avetian, Thuy Ho, Graeme F Murray, Ian M. Bouligny, Keri Maher
Journal: Blood
Blood (2024) 144 (Supplement 1): 7389.
https://doi.org/10.1182/blood-2024-206144
Published: 2024
Journal Articles

Prognostic Impact of PTPN11 mutations in Acute Myeloid Leukemia

Thuy Ho, Luke Kicklighter, George Avetian, Graeme F Murray, Ian M. Bouligny, Hyun Lee, Natasha Dziarnowski, Keri Maher
Journal: Blood
Blood (2024) 144 (Supplement 1): 6120.
https://doi.org/10.1182/blood-2024-211478
Published: 2024
Journal Articles

Hypomethylating Agents and Venetoclax or Hypomethylating Agents Alone in Acute Myeloid Leukemia in Patients with Significant Comorbidities

Graeme F Murray, Ian M. Bouligny, Thuy Ho, Juhi F Gohr, Keri Maher
Journal: Blood
Blood (2024) 144 (Supplement 1): 6083.
https://doi.org/10.1182/blood-2024-193042
Published: 2024
Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven M. Kornblau, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Anne Meyer, Xuelin Huang, Guillermo Garcia-Manero
Journal: Blood
Blood (2024) 144 (Supplement 1): 4601.
https://doi.org/10.1182/blood-2024-204040
Published: 2024
Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Ian M. Bouligny, Hagop M. Kantarjian, Musa Yilmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Guillermo Montalban-Bravo, Nicholas J. Short, Yesid Alvarado Valero, Elias Jabbour, Nitin Jain, Naveen Pemmaraju, Danielle Hammond, Kelly S. Chien, Koichi Takahashi, Ghayas C. Issa, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 734.
https://doi.org/10.1182/blood-2024-203459
Published: 2024
Journal Articles

Comparison of Cytoreductive Therapies for Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: A Perspective on the Updated American Society for Apheresis Guidelines

George Avetian, Thuy Ho, Ian M. Bouligny, Hyun Lee, Keri Maher
Journal: Blood
Blood (2024) 144 (Supplement 1): 7637.
https://doi.org/10.1182/blood-2024-206090
Published: 2024
Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Ian M. Bouligny, Hagop M. Kantarjian, Musa Yilmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Guillermo Montalban-Bravo, Nicholas J. Short, Yesid Alvarado Valero, Nitin Jain, Naveen Pemmaraju, Danielle Hammond, Kelly S. Chien, Koichi Takahashi, Ghayas C. Issa, Hussein A. Abbas, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2024) 144 (Supplement 1): 446.
https://doi.org/10.1182/blood-2024-203938
Published: 2024
Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero, Courtney D. DiNardo, Farhad Ravandi, Naveen Pemmaraju, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Sherry Pierce, Meghan Anne Meyer, Xuelin Huang, Guillermo Garcia-Manero
Journal: Blood
Blood (2024) 144 (Supplement 1): 3212.
https://doi.org/10.1182/blood-2024-205186
Published: 2024
Journal Articles

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11745–11746.
https://doi.org/10.1182/blood-2022-171129
Published: 2022
Journal Articles

Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11744.
https://doi.org/10.1182/blood-2022-171018
Published: 2022
Journal Articles

Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11742–11743.
https://doi.org/10.1182/blood-2022-170836
Published: 2022
Journal Articles

Back in JAK - Real-World Analysis of JAK mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11812–11813.
https://doi.org/10.1182/blood-2022-171165
Published: 2022
Journal Articles

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11842–11843.
https://doi.org/10.1182/blood-2022-170972
Published: 2022
Journal Articles

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 5281–5282.
https://doi.org/10.1182/blood-2022-171063
Published: 2022
Journal Articles

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 6335–6336.
https://doi.org/10.1182/blood-2022-170907
Published: 2022
Journal Articles

Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 13305–13306.
https://doi.org/10.1182/blood-2022-171223
Published: 2022
Journal Articles

Minority Health Disparities in Acute Myeloid Leukemia: A Metropolitan, Single-Center Retrospective Analysis

Keri R. Maher, Ian M. Bouligny
Journal: Blood
Blood (2021) 138 (Supplement 1): 1987.
https://doi.org/10.1182/blood-2021-153642
Published: 2021
Journal Articles

Differential Outcomes of Salvage with FLAG-IDA and Venetoclax-Based Regimens in Relapsed and Refractory Acute Myeloid Leukemia

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2021-153690
Published: 2021
Journal Articles

The Impact of Molecular and Cytogenetic Clonal Evolution on Survival in Relapsed/Refractory AML

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 4452.
https://doi.org/10.1182/blood-2021-153194
Published: 2021